Zacks Research Has Positive View of Novartis FY2026 Earnings

Novartis AG (NYSE:NVS) – Zacks Research upped their FY2026 earnings per share (EPS) estimates for shares of Novartis in a research note issued on Monday, August 24th. Zacks Research analyst Team now anticipates that the company will earn $8.83 per share for the year, up from their prior estimate of $8.82. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share. Zacks Research also issued estimates for Novartis’ Q4 2027 earnings at $2.40 EPS and Q2 2028 earnings at $2.72 EPS.

Other research analysts have also recently issued reports about the stock. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Stock Performance

NYSE NVS opened at $158.00 on Tuesday. The company has a fifty day moving average price of $154.48 and a 200-day moving average price of $153.72. The firm has a market cap of $301.48 billion, a price-to-earnings ratio of 23.83, a PEG ratio of 2.72 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis has a 1 year low of $121.57 and a 1 year high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

Institutional Investors Weigh In On Novartis

Several large investors have recently made changes to their positions in NVS. Arlington Trust Co LLC purchased a new position in shares of Novartis in the 4th quarter worth about $25,000. Archer Investment Corp increased its holdings in Novartis by 93.0% during the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after buying an additional 80 shares during the last quarter. Highland Investment Advisors LLC bought a new stake in Novartis in the second quarter worth about $25,000. Evolution Wealth Management Inc. raised its position in Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after acquiring an additional 138 shares during the period. Finally, Atlatl Advisers LLC purchased a new position in Novartis in the second quarter valued at about $26,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.